China Innovation Takes Another Step: Merck KGAA Ties Up With BeiGene On Global Agreement For BRAF Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
In a win for China’s innovation strategy, leading local player BeiGene partners its second-generation BRAF inhibitor, which may have opportunities beyond metastatic melanoma where Roche has made its mark with BRAF inhibitor Zelboraf.